^
    1d
    A Clinical Study of MK-1084 With Rosuvastatin and Metformin in Healthy People (MK-1084-016) (clinicaltrials.gov)
    P1, N=16, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    metformin • MK-1084
    2d
    Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study. (PubMed, Eur J Cancer)
    This pooled analysis confirmed the robust efficacy and manageable safety of garsorasib in KRAS G12C-mutated NSCLC.
    P1/2 data • Retrospective data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Anfangning (garsorasib)
    3d
    Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial. (PubMed, Lancet Respir Med)
    Glecirasib combined with sitneprotafib showed promising efficacy and manageable safety in patients with advanced KRASG12C -mutated NSCLC, particularly among those who had not received previous treatment. These findings support the evaluation of this combination in a phase 3 trial comparing this chemotherapy-free regimen to current standard of care in this patient group.
    P1/2 data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Airuikai (glecirasib) • sitneprotafib (JAB-3312)
    4d
    Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC. (PubMed, J Thorac Oncol)
    Olomorasib + pembrolizumab demonstrated manageable safety and promising antitumor activity in patients with KRAS G12C-mutant advanced NSCLC across PD-L1 expression levels, especially in the high PD-L1 first-line setting.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • olomorasib (LY3537982)
    6d
    A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Genentech, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    divarasib (RG6330)
    6d
    KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) (clinicaltrials.gov)
    P2, N=130, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2 trial
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • pemetrexed • MK-1084
    7d
    Krascendo 170: A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (clinicaltrials.gov)
    P1/2, N=320, Recruiting, Hoffmann-La Roche | N=240 --> 320
    Enrollment change
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • divarasib (RG6330)
    9d
    Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation (clinicaltrials.gov)
    P1/2, N=37, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Dec 2025 --> Aug 2026
    Enrollment open • Trial initiation date
    |
    KRAS (KRAS proto-oncogene GTPase) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 overexpression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib)
    9d
    Breakthroughs in KRAS G12C-mutant advanced colorectal cancer: from mechanisms to clinical practice (PubMed, Zhonghua Wei Chang Wai Ke Za Zhi)
    Recent phase I/II trials of KRAS G12C inhibitors have shown promising results, and the phase III CodeBreaK 300 study confirmed that sotorasib combined with panitumumab significantly improved efficacy compared with standard treatment, establishing a new therapeutic option for KRAS G12C-mutant metastatic CRC. Strategies under investigation include targeting alternative signaling pathways, developing next-generation inhibitors and specific degraders, and exploring multi-mechanism or multi-target combination strategies. This review systematically outlines the development of KRAS G12C inhibitors in mCRC, summarizes resistance mechanisms, and discusses emerging combination regimens, aiming to provide a theoretical basis and future directions for treatment optimization.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Vectibix (panitumumab) • Lumakras (sotorasib)
    13d
    Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC (clinicaltrials.gov)
    P3, N=472, Not yet recruiting, Jemincare
    New P3 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    docetaxel • sosimerasib (HBI-2438)
    14d
    A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    BI 1823911 • BI 1701963 • midazolam hydrochloride
    16d
    A Study of Olomorasib (LY3537982) in Healthy Japanese Participants (clinicaltrials.gov)
    P1, N=188, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    olomorasib (LY3537982)